Sarcoidosis. Disease progression based on radiological and functional course: Predictive factors

Casal, Ana; Suárez-Antelo, Juan; Soto-Feijóo, Roi; Ferreiro, Lucía; Rodríguez-Núñez, Nuria; Lama, Adriana; Riveiro, Vanessa; Toubes, Ma Elena; Lourido, Tamara; Ricoy, Jorge; Rábade, Carlos; Zamarrón, Carlos; Rodríguez, Carlota; Abelleira, Romina; Álvarez-Dobaño, José Manuel; Golpe, Antonio; Alegría, Anxo Martínez de; Antúnez, José Ramón; Gudé, Francisco; Valdés, Luis

doi:10.1016/j.hrtlng.2022.06.020

Cited by 7 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike our study results, McDonnell et al in their retrospective observational study found that low DLCO at sarcoidosis presentation may identify patients without Löfgren's syndrome who are more likely to develop physiological progression [52]. However, other authors [23,53] did not confirm their findings.…”

Section: Discussioncontrasting

confidence: 99%

“…Other specific potential prognostic factors found in other studies, but not confirmed or not investigated in our study are older patients' age [23,53,54], C reactive protein [52], and extrapulmonary involvement of disease [7,53].…”

Section: Discussionsupporting

confidence: 51%

“…Although the course of sarcoidosis is highly variable [21], in most cases sarcoidosis does not progress [22,23]. In our study group, PFT indices and CT lung parenchyma changes remained stable or even improved for most patients (approximately 80% and 90% of all the patients respectively) at 2 years follow-up.…”

Section: Discussionmentioning

confidence: 55%

See 2 more Smart Citations

CD4+CD31+ and CD4+CD44+ Lymphocytes in Peripheral Blood, CD8+CD31+ and CD8+CD103+ Lymphocytes in Bronchoalveolar Lavage Fluid, and Pulmonary Nodules in Predicting the Course of Pulmonary Sarcoidosis

Danila¹,

Aleksonienė²,

Besusparis³

et al. 2023

Preprint

View full text Add to dashboard Cite

The search for biological markers, which allow a relatively accurate assessment of the individual course of pulmonary sarcoidosis at the time of diagnosis remains one of the research priorities in this field of pulmonary medicine. The aim of our study was to investigate possible prognostic factors for pulmonary sarcoidosis with a special focus on cellular immune inflammation markers. 2 years follow-up of the study population after initial prospective and simultaneous analysis of lymphocyte activation markers expression in the blood, as well as bronchoalveolar lavage fluid (BALF), and lung biopsy tissue of patients with newly diagnosed pulmonary sarcoidosis, was done. We found that some blood and BAL fluid immunological markers and lung computed tomography (CT) patterns have been associated with a different course of sarcoidosis. We revealed five markers that had a significant negative association with the course of sarcoidosis (worsening pulmonary function tests and/or the chest CT changes) – blood CD4+CD31+ and CD4+CD44+ T lymphocytes, BALF CD8+CD31+ and CD8+CD103+ T lymphocytes and a number of lung nodules on chest CT at the time of the diagnosis. Cut-off values, sensitivity, specificity, and odds ratio for predictors of sarcoidosis progression were calculated. These markers may be reasonable predictors of sarcoidosis progression.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 51%

See 1 more Smart Citation

CD4+CD31+ and CD4+CD44+ Lymphocytes in Peripheral Blood, CD8+CD31+ and CD8+CD103+ Lymphocytes in Bronchoalveolar Lavage Fluid, and Pulmonary Nodules in Predicting the Course of Pulmonary Sarcoidosis

Danila¹,

Aleksonienė²,

Besusparis³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Predicting prognosis is a challenging task. Historically, chest radiographic stages proposed by Scadding in the 1960s were used to assess pulmonary involvement [70], but it has been suggested that they are poorly correlated with disease severity and pulmonary function and not useful for predicting sarcoidosis progression [71].…”

Section: Prognosismentioning

confidence: 99%

“…Several epidemiological factors appear to be associated with prognosis. Older age is an important predictor for disease progression and a prolonged disease course [71,72]. African Americans present more often with extrapulmonary manifestations and advanced radiographic stages [73], and they are more likely to have a worse clinical course [74].…”

Section: Prognosismentioning

confidence: 99%

Sarcoidosis: Epidemiology and clinical insights

et al. 2023

View full text Add to dashboard Cite

Sarcoidosis is characterized by noncaseating granulomas which form in almost any part of the body, primarily in the lungs and/or thoracic lymph nodes. Environmental exposures in genetically susceptible individuals are believed to cause sarcoidosis. There is variation in incidence and prevalence by region and race. Males and females are almost equally affected, although disease peaks at a later age in females than in males. The heterogeneity of presentation and disease course can make diagnosis and treatment challenging. Diagnosis is suggestive in a patient if one or more of the following is present: radiologic signs of sarcoidosis, evidence of systemic involvement, histologically confirmed noncaseating granulomas, sarcoidosis signs in bronchoalveolar lavage fluid (BALF), and low probability or exclusion of other causes of granulomatous inflammation. No sensitive or specific biomarkers for diagnosis and prognosis exist, but there are several that can be used to support clinical decisions, such as serum angiotensin‐converting enzyme levels, human leukocyte antigen types, and CD4 Vα2.3+ T cells in BALF. Corticosteroids remain the mainstay of treatment for symptomatic patients with severely affected or declining organ function. Sarcoidosis is associated with a range of adverse long‐term outcomes and complications, and with great variation in prognosis between populations. New data and technologies have moved sarcoidosis research forward, increasing our understanding of the disease. However, there is still much left to be discovered. The pervading challenge is how to account for patient variability. Future studies should focus on how to optimize current tools and develop new approaches so that treatment and follow‐up can be targeted to individuals with more precision.

show abstract

Swollen cervical lymph nodes and centrilobular pulmonary nodules due to sarcoidosis

Pizzolato,

Agati,

Negri

et al. 2025

Rare and Interstitial Lung Diseases

View full text Add to dashboard Cite

Sarcoidosis. Disease progression based on radiological and functional course: Predictive factors

Cited by 7 publications

References 41 publications

CD4+CD31+ and CD4+CD44+ Lymphocytes in Peripheral Blood, CD8+CD31+ and CD8+CD103+ Lymphocytes in Bronchoalveolar Lavage Fluid, and Pulmonary Nodules in Predicting the Course of Pulmonary Sarcoidosis

CD4+CD31+ and CD4+CD44+ Lymphocytes in Peripheral Blood, CD8+CD31+ and CD8+CD103+ Lymphocytes in Bronchoalveolar Lavage Fluid, and Pulmonary Nodules in Predicting the Course of Pulmonary Sarcoidosis

Sarcoidosis: Epidemiology and clinical insights

Swollen cervical lymph nodes and centrilobular pulmonary nodules due to sarcoidosis

Contact Info

Product

Resources

About